A Bayesian adaptive phase I/II clinical trial design with late-onset competing risk outcomes
{{output}}
Early-phase dose-finding clinical trials are often subject to the issue of late-onset outcomes. In phase I/II clinical trials, the issue becomes more intractable because toxicity and efficacy can be competing risk outcomes such that the occurrence of the first... ...
